drugset / Trial / NCT00319800
Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine whether in docetaxel pretreated advanced NSCLC patients with favorable clinical parameter(s) gefitinib can produce different outcomes from patients without favorable clinical parameter treated with irinotecan.
Timeline
- Start
- 2006-02
- Primary completion
- —
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | — | — |
| Subject | Irinotecan | Small molecule | — | — |